Koers Cytokinetics, Inc. Nasdaq
Aandelen
US23282W1009
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
Omzet 2024 * | 32,14 mln. 29,93 mln. | Omzet 2025 * | 72,93 mln. 67,93 mln. | Marktkapitalisatie | 6,36 mld. 5,92 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -490 mln. -456 mln. | Nettowinst (verlies) 2025 * | -494 mln. -460 mln. | EV/omzet 2024 * | 183 x |
Nettoliquiditeiten 2024 * | 464 mln. 432 mln. | Nettoliquiditeiten 2025 * | 474 mln. 442 mln. | EV/omzet 2025 * | 80,7 x |
K/w-verhouding 2024 * |
-12,3
x | K/w-verhouding 2025 * |
-12,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,5% |
Recentste transcriptie over Cytokinetics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 01-07-98 |
Kari Loeser
CMP | Compliance Officer | - | 01-11-21 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-20 |
Edward Kaye
BRD | Director/Board Member | 75 | 20-05-16 |
Santo Costa
BRD | Director/Board Member | 78 | 01-10-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,82% | 121 mld. | |
+20,35% | 113 mld. | |
+17,47% | 26,02 mld. | |
-25,31% | 19,39 mld. | |
-19,51% | 15,91 mld. | |
-19,67% | 15,09 mld. | |
-46,87% | 15,06 mld. | |
+62,55% | 14,93 mld. | |
+6,34% | 13,85 mld. |
- Beurs
- Aandelen
- Koers CYTK
- Koers